A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults (VTIME)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The proposed randomized controlled trial will evaluate the effects of treadmill training augmented with virtual reality on fall risk.
300 older adults with a history of falls will be recruited to participate in this study. This will include older adults (n=100), patients with mild cognitive impairment (MCI) (n=100), and patients with Parkinson's disease (PD)(n=100). Subjects will be randomly assigned to the intervention group (treadmill training with virtual reality) or to the active-control group (treadmill training without virtual reality). Each person will participate in a training program set in an outpatient setting 3 times per week for 6 weeks. Assessments will take place before, after, and 1 month and 6 months after the completion of the training.
| Condition | Intervention |
|---|---|
|
Elderly Adults Parkinson Mild Cognitive Disorder |
Other: TT+VR Other: TT alone |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | V-TIME: A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults, Patients With Parkinson's Disease and Individuals With Mild Cognitive Impairments |
- Falls rate [ Time Frame: 6 months post intervention ] [ Designated as safety issue: No ]The primary outcome measure of the study is fall rate. Participants will keep a falls calendar for 6 months post intervention. Each time the participant falls he/she will tick the date on the calendar. These calendars will be returned to the researchers once a month in a pre-addressed envelope.
- Gait [ Time Frame: 6 months post intervention ] [ Designated as safety issue: No ]Gait speed and gait variability under usual and dual task conditions and while negotiating physical obstacles will be measured. Participants will be asked to walk in a well-lit corridor under 3 conditions each of 1 minute: i) walking in a comfortable speed, ii) walking while subtracting 3s from a predefined number (dual task), iii) walking while negotiating two obstacles placed on the floor at specific locations. Spatial-temporal gait characteristics (e.g., gait speed (m/s), stride length (m), stride time (s), swing time (%), asymmetry, and step width (cm)) will be determined. Endurance will be assessed using the 2 Minute Walk Test.
- Cognitive function [ Time Frame: 6 months post intervention ] [ Designated as safety issue: No ]Cognitive function will be assessed using a computerized neuropsychological test battery (Mindstreams, NeuroTrax Corp., NJ). In addition, we will also include standardized neuropsychological tests such as the Montreal Cognitive Assessment (MoCA); The Trail Making Test (TMT) and the Verbal Fluency test.
- Balance and mobility [ Time Frame: 6 months post intervention ] [ Designated as safety issue: No ]The Four Square Step Test (FSST), The Short Physical Performance Battery (SPPB) and the mini-Balance Evaluation Systems Test (mini-BESTest) will be used to assess mobility. Community ambulation will be assessed using The Physical Activity Scale for the Elderly (PASE) and a tri-axial accelerometer (Axivity Ltd.) which will be worn by the participants for 7 days to quantify and monitor stepping and physical activity.
- Quality of life [ Time Frame: 6 months post intervention ] [ Designated as safety issue: No ]The SF-36 Health Survey, a generic self-report questionnaire designed to address health related quality of life will be used. Fear of Falling will be evaluated using the Falls Efficacy Scale-International.
| Estimated Enrollment: | 300 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: TT+VR
The training will consist of walking on the treadmill while negotiating obstacles in a virtual reality simulation.Training will be provided3 times a week for a duration of 6 weeks (total of 18 sessions).
|
Other: TT+VR
subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
Other Name: training on a treadmill with virtual reality
|
|
Active Comparator: TT alone
The training will consist of walking on the treadmill 3 times a week for a duration of 6 weeks (total of 18 sessions).
|
Other: TT alone
The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
Other Name: treadmill training
|
Detailed Description:
A prospective, single blinded, parallel group, randomized controlled trial with 6 month follow-up will be employed to investigate the effects of treadmill training augmented with virtual reality on fall risk. The study will include 300 older participants who have experienced two or more falls in the previous 6 months. Participants will be randomized to either the intervention or control group. The intervention group will receive 18 sessions of Treadmill Training with Virtual Reality (TT+VR) and the active control comparison will receive 18 training sessions of treadmill training alone (TT) without the VR simulation All interventions will be delivered by therapists trained in the standard protocols. All subjects will be trained 3 times a week for 6 weeks, each session will last approximately 45 minutes.Training progression will be based on increasing both motor and cognitive challenges, individualized to the participant's level of performance.
Primary outcome measures:
The primary outcome measure of the study is fall rate for 6 months post intervention. Secondary outcome measures will include gait speed and gait variability under usual and dual task conditions and while negotiating physical obstacles will be measured. Endurance will be assessed using the 2 Minute Walk Test and mobility will be assessed using the Four Square Step Test (FSST), The Short Physical Performance Battery (SPPB) and the mini-Balance Evaluation Systems Test (mini-BESTest). Community ambulation will be assessed using a tri-axial accelerometer ('Axivity' Ltd.)which will be worn by the participants for 7 days. Cognitive function will be assessed using a computerized neuropsychological test battery (Mindstreams, 'NeuroTrax' Corp., NJ) as well as standardized neuropsychological tests (Montreal Cognitive Assessment,The Trail Making Test; Verbal Fluency). Quality of life will be evaluated using the SF-36 Health Survey
Eligibility| Ages Eligible for Study: | 60 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 2 or more falls within 6 months prior to the beginning of the study
- Aged 60-85 years
- Able to walk for 5 minutes unassisted
- Adequate hearing and vision capabilities.
- Stable medication for the past 1 month and anticipated over a period of 6 months
Exclusion Criteria:
- Psychiatric co-morbidity
- Clinical diagnosis of dementia or other severe cognitive impairment (MMSE<24)
- History of stroke, traumatic brain injury or other neurological disorders (other than PD and MCI, for those groups)
- Acute lower back or lower extremity pain, peripheral neuropathy, rheumatic and orthopaedic diseases
- Unstable medical condition in the past 6 months
- Unable to comply with the training
- Interfering therapy
Contacts and Locations| Contact: Anat Mirelman, PhD | +972 3 6973960 | anatmi@tasmc.health.gov.il |
| Belgium | |
| Department of Rehabilitation Sciences, Katholieke Universiteit Leuven | Not yet recruiting |
| Leuven, Belgium | |
| Contact: Alice Nieuwboer, PhD Alice.Nieuwboer@faber.kuleuven.be | |
| Israel | |
| Tel Aviv Sourasky Medical Center | Not yet recruiting |
| Tel Aviv, Israel, 64239 | |
| Contact: Anat Mirelman, PhD +972 3 6973960 anatmi@tasmc.health.gov.il | |
| Principal Investigator: Jeff M Hausdorff, PhD | |
| Italy | |
| Department of Neurosciences Universita Degli Studi Di Genova, Italy | Not yet recruiting |
| Genova, Italy | |
| Contact: Elisa Pelosin, PhD elisapelosin@yahoo.it | |
| Netherlands | |
| Department of Geriatric Medicine and Neurology, Radboud University Nijmegen Medical Center The Netherlands | Not yet recruiting |
| Nijmegen, Netherlands | |
| Contact: Miriam Reelick, PhD M.Reelick@ger.umcn.nl | |
| United Kingdom | |
| Institute for Aging and Health, University of Newcastle, UK | Not yet recruiting |
| Newcastle, United Kingdom | |
| Contact: Lynn Rochester, PhD Lynn.rochester@newcastle.ac.uk | |
| Principal Investigator: | Jeffrey M Hausdorff, PhD | Tel-Aviv Sourasky Medical Center |
More Information
No publications provided by Tel-Aviv Sourasky Medical Center
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Tel-Aviv Sourasky Medical Center |
| ClinicalTrials.gov Identifier: | NCT01732653 History of Changes |
| Other Study ID Numbers: | TASMC-12-NG-0505-CTIL, VTIME |
| Study First Received: | November 5, 2012 |
| Last Updated: | November 19, 2012 |
| Health Authority: | Israel: Ethics Commission United Kingdom: Research Ethics Committee Belgium: Ethics Committee Italy: Ethics Committee Netherlands: Independent Ethics Committee |
Keywords provided by Tel-Aviv Sourasky Medical Center:
|
virtual reality, falls, elderly, Parkinson's disease, MCI |
Additional relevant MeSH terms:
|
Cognition Disorders Parkinson Disease Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Parkinsonian Disorders Basal Ganglia Diseases |
Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |
ClinicalTrials.gov processed this record on May 23, 2013